Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly reduce stroke risk in patients with chronic respiratory disease and diabetes. Longer GLP-1RA use further decreases this risk, though initial use may increase cardiac arrhythmia risk temporarily.
Area Of Science
- Cardiovascular Medicine
- Endocrinology
- Pulmonology
Background
- Patients with chronic respiratory disease and diabetes (CD) face elevated risks for cardiovascular events, including stroke and heart disease.
- The COVID-19 pandemic has highlighted the complex interplay between chronic conditions and acute infections, potentially exacerbating cardiovascular risks.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for diabetes management, with emerging evidence of cardiovascular benefits.
Purpose Of The Study
- To evaluate the impact of GLP-1 receptor agonists (GLP-1RAs) on the incidence of stroke and heart disease in patients with chronic respiratory disease and diabetes (CD).
- To investigate the association between the duration of GLP-1RA use and cardiovascular outcomes in this specific patient cohort.
- To explore the influence of lag time between diabetes diagnosis and initiation of GLP-1RA therapy on stroke risk.
Main Methods
- A retrospective cohort study utilizing the Taiwan National Health Insurance Research Database from 1998 to 2019.
- Propensity score matching was employed to balance baseline characteristics between GLP-1RA users and non-users.
- Time-dependent methods were used to analyze the risks of stroke, ischemic stroke, hemorrhagic stroke, and cardiac arrhythmia.
Main Results
- GLP-1RA users demonstrated significantly lower overall risks of stroke (aSHR 0.76), ischemic stroke (aSHR 0.77), and hemorrhagic stroke (aSHR 0.69) compared to non-users.
- Sustained GLP-1RA use (≥351 days) was associated with a substantially reduced stroke risk (aSHR 0.35).
- An increased incidence of cardiac arrhythmia was observed in GLP-1RA users initially (aSHR 1.36), but this risk diminished with longer-term use (≥351 days).
Conclusions
- GLP-1RA therapy is associated with a significant reduction in stroke risk for patients with chronic respiratory disease and diabetes.
- Both early initiation and longer duration of GLP-1RA use appear beneficial in mitigating stroke risk within the CD cohort.
- While initial GLP-1RA use may transiently increase cardiac arrhythmia risk, this effect is mitigated by prolonged treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...